AMR Control SUPPLEMENT

THE CHALLENGE FOR THE CANCER COMMUNITY 

06 AMR Insights Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance

07 Foreword Anil D’Cruz, President, Union for International Cancer Control

08 Introduction: The importance of addressing antimicrobial resistance for better cancer care outcomes Shalini Jayasekar Zürn, Senior Advocacy Manager; Sonali Johnson, Head of Knowledge, Advocacy and Policy; and Cary Adams, Chief Executive Officer, Union for International Cancer Control

10 AMR Insights Ulrika Årehed Kågström, Secretary General, Swedish Cancer Society

THE CHALLENGE OF AMR
12 Interview: Malin GrapeSwedish Ambassador for Antimicrobial Resistance

14 AMR Insights Yehoda Martei, Assistant Professor of Medicine and the Vice Chief of Diversity, Inclusion and Health Equity in the Division of Hematology-Oncology, University of Pennsylvania, USA

15 Five barriers to addressing antimicrobial resistance  Rohan Kocharekar, Research Fellow, Chatham House, UK

17 Sponsored feature We need a global, legally binding antibiotic treaty – now! Norwegian Cancer Society

18 The impact of AMR on cancer care – reinvigorating the R&D pipeline Lesley Ogilvie, Interim Secretariat co-Lead, Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub, Berlin, Germany; Ralf Sudbrak, Interim Secretariat co-Lead, Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub, Berlin, Germany and Stefan Schwartz, Senior Physician, Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité – Universitätsmedizin Berlin, corporate member, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

23 Sponsored feature Antimicrobial resistance: Our future depends on what we do today BD

24 We need a “moonshot project” to control antimicrobial resistance  Magnus Løvold, Co-founder, Norwegian Academy of International Law, Oslo, Norway; Sigrid Bratlie, Strategic Advisor, The Norwegian Cancer Society, Norway;  Kjølv Egeland, Post-Doctoral Fellow, Centre for International Studies, Sciences Po, Paris, France and Torbjørn Graff Hugo, Co-founder, Norwegian Academy of International Law, Oslo, Norway

28 AMR Insights David E Greenberg, Professor of Infectious Diseases and Microbiology, University of Texas Southwestern Medical Center, USA

29 Patient story: Superbugs and You: Russell McGowan tells his story

30 AMR Insights Kevin Outterson, Professor of Law, Boston University and Executive Director, CARB-X

AMR AND CANCER TREATMENT
32 Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward Amila K Nanayakkara, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA; Helen W Boucher, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA; Vance G Fowler, Jr,  Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Amanda Jezek, Infectious Diseases Society of America, Arlington, Virginia, USA; Kevin Outterson, CARB-X, Boston, Massachusetts, USA; Boston University School of Law, Boston, Massachusetts, USA and David E Greenberg, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA; Department of Microbiology, University of Texas Southwestern, Dallas, Texas, USA

46 The impact of antibiotic resistance on cancer treatment, especially in low- and middle-income countries, and the way forward  Mirfin Mpundu, Director, ReAct Africa; Andrea Caputo, Global Health Adviser, ReAct Europe; Anna Karin Sjöblom, Director, ReAct and Otto Cars, Founder, ReAct and Senior Strategic Adviser

51 Sponsored feature Antimicrobial Resistance Fighter Coalition

52 Leveraging information systems that integrate cancer registries with microbiology databases to improve clinical care and address antimicrobial resistance in oncology Scott C Howard, Professor, University of Tennessee Health Science Center, Memphis, USA; Miguela A Caniza, Professor, St Jude Children’s Research Hospital, Memphis, USA and Co-Chair, Global Health Network Supportive Care Working Group, International Society of Pediatric Oncology, Meierskappel, Switzerland; Ryan Combs, Vice President of Analytics, Resonance, Memphis, USA; Aman Patel, Chief Technology Officer, Resonance, Memphis, USA; Ligia Fu, Chief, Pediatric Oncology Ward, Hospital Escuela Tegucigalpa, Honduras; Jennifer A Lowe, Vice President of Clinical Trials, Resonance, Memphis, USA and Catherine G Lam, Director, Health Systems Unit, Global Pediatric Medicine Department and Co-Director, World Health Organization Collaborating Centre for Childhood Cancer, St Jude Children’s Research Hospital, Memphis, USA

60 AMR InsightsDr Zipporah Ali, Palliative Care Physician and Public Health Specialist

CONSERVING ANTIBIOTICS
62 Antimicrobial stewardship and optimizing antimicrobial use in the cancer community Deborah Tong, Technical Officer, Antimicrobial Stewardship and Awareness Unit, Global Coordination and Partnership Department, Division of Antimicrobial Resistance, World Health Organization and Haileyesus Getahun, Director, Global Coordination and Partnership Department, Division of Antimicrobial Resistance, World Health Organization

65 Being AWaRe of the risk of inappropriate antibiotic use in people living with cancer  Mike Sharland, Centre for Neonatal and Paediatric Infection, St George’s University London, UK; Veronica Zanichelli, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Bishal Gyawali, Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, Canada; Manju Sengar, Department of Medical Oncology, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, India; Bernadette Cappello, Technical Officer, Essential Medicines, Access to Medicines and Health Products Division, World Health Organization, Geneva, Switzerland; Lorenzo Moja, Scientist, Essential Medicines, Access to Medicines and Health Products Division, World Health Organization, Geneva, Switzerland and Benedikt Huttner, Team Lead, Essential Medicines, Access to Medicines and Health Products Division, World Health Organization, Geneva, Switzerland 

69 AMR Insights Sonali Johnson, Head of Knowledge, Advocacy and Policy, Union for International Cancer Control

70Case study: mHealth and a blended learning approach to antimicrobial stewardship in Abia State Kelechi Eguzo, Marjorie Bash Foundation, Aba, Nigeria; Chukwuemeka Oluoha, Abia State University, Uturu, Nigeria; Usenime Akpanudo, Harding University, Searcy, USA; Chinenye Onodugo, University of Nigeria Teaching Hospital, Enugu, Nigeria; Kingsley Nnah, Marjorie Bash College of Health Sciences and Technology, Aba, Nigeria; Peace Egharevba, University of Benin, Benin City, Nigeria; Peace Ndukwe, Abia State Ministry of Health, Umuahia, Nigeria and Onyechere Nwokocha, Abia State Ministry of Health, Umuahia, Nigeria

72 AMR Insights Dr Zisis Kozlakidis, Head of Laboratory Services and Biobanking, International Agency for Research on Cancer, World Health Organization (IARC/WHO)

COUNTERING THE AMR CHALLENGE
74 Diagnostics: An essential tool to combat the ongoing pandemic of antimicrobial resistance  Cecilia Ferreyra, Director, AMR Programme, FIND, Geneva, Switzerland; Birgitta Gleeson, Scientist, FIND, Geneva, Switzerland and Daniel G Bausch, Senior Director of Emerging Threats and Global Health Security at FIND, Geneva, Switzerland

78 The AMR challenge – Perspectives from the life science industry Luka Srot, Manager, Health Security, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Geneva, Switzerland and Diane Flayhart, Global Program Leader, AMR, Becton Dickinson, USA

83 Improving the lives of cancer patients is inextricably linked to tackling drug resistance Jennifer Cohn, Rohit Malpani and Michelle Childs,  Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland          

88 AMR Insights Dr Mohamad Abu Rasheed Hadi, Scientific Advisor and Head of the Professional Development and Scientific Research, Qatar Cancer Society

89 Resistance beyond antibiotics – antifungal resistance Lillian Sung, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada

RESOURCES
94  Union for International Cancer Control (UICC): Leading the cancer community

96  The UICC-led Task Force on Antimicrobial Resistance and Cancer Care  

Acknowledgements